# Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin

> **NCT05581407** · PHASE1 · COMPLETED · sponsor: **LiteVax BV** · enrollment: 60 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** TETRALITE

## Key facts

- **NCT ID:** NCT05581407
- **Lead sponsor:** LiteVax BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-03
- **Primary completion:** 2023-08-03
- **Final completion:** 2023-10-23
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05581407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05581407, "Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05581407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*